Xenotransplantation Is Serious Business

The following was written in response to a Notebook item in your March 2, 1998 issue [The Scientist, 12[5]:27, March 2, 1998]: Jeff Getty may be the brunt of gauche humor regarding his primate blood relatives. His assessment of the anti- xenotransplantation sentiment among scientific and medical professionals and the lay public, however, is simply wrong. There is no "deep-seated psychological barrier" to using animal cells, tissues, and organs in human patients. What exists instead is a very r

Written byJohn Mcardle
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

The following was written in response to a Notebook item in your March 2, 1998 issue [The Scientist, 12[5]:27, March 2, 1998]:

Jeff Getty may be the brunt of gauche humor regarding his primate blood relatives. His assessment of the anti- xenotransplantation sentiment among scientific and medical professionals and the lay public, however, is simply wrong. There is no "deep-seated psychological barrier" to using animal cells, tissues, and organs in human patients. What exists instead is a very real threat to public health.

Getty and his xeno-cohorts are proposing experimental procedures that could cause far worse medical devastation than that claimed for AIDS or organ shortages. There is more at stake with this issue than egos of transplant surgeons, the profits of pharmaceutical companies, and the survival of individual patients.

The world's leading experts on primate retroviruses all agree that such a deadly scenario is a realistic possibility. Consider that ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies